Archives
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-07
-
BIBP 3226: A Causal Probe for Cardiac Arrhythmia
2026-08-20
BIBP 3226 trifluoroacetate provides a defined pharmacological probe for separating NPY Y1 and NPFF signaling in mechanistic studies. This article translates the adipose-neural arrhythmia model into practical assay logic, controls, and interpretation strategies.
-
Brassinolide for Reproducible Cell Assays
2026-08-20
This scenario-driven guide explains how Brassinolide, SKU A3265, can be incorporated into cell viability, proliferation, and apoptosis workflows without confusing solvent effects with biological activity. It covers formulation, assay controls, interpretation of PC-3 apoptosis evidence, and practical product-selection criteria for biomedical laboratories.
-
ATP Solution for mRNA-LNP Workflows
2026-08-19
Discover how a high-purity ATP Solution supports IVT mRNA production, kinase validation, ligation, and phosphorylation assays connected to localized p21 mRNA-LNP research. Practical dilution guidance, workflow controls, and troubleshooting help translate Adenosine-5'-triphosphate handling into more reproducible molecular biology experiments.
-
Cationic Lipid Pairs Redirect mRNA LNPs to the Lung
2026-08-19
Zeng and colleagues developed a cationic lipid pair strategy that combines a liver-targeted ionizable lipid with its quaternary ammonium derivative to shift four-component lipid nanoparticles from liver-biased toward lung-enriched mRNA delivery. The study shows that parent-lipid performance is an important design criterion and that the approach can be extended to clinically used ionizable lipids, including SM-102 and ALC-0315.
-
Z-VDVAD-FMK for Caspase-2 Apoptosis Workflows
2026-08-18
Z-VDVAD-FMK helps researchers test whether caspase-2 contributes to mitochondrial and nuclear apoptosis, while its activity against caspases-3 and -7 requires careful interpretation. This workflow guide connects inhibitor treatment with caspase activity measurement, cytochrome c analysis, DDX23 signaling, and orthogonal cell-death readouts.
-
Triacetin Workflows for Cell and Metabolic Assays
2026-08-18
Triacetin supports distinct workflows spanning glioblastoma apoptosis assays, metabolic regulation studies, and ocular formulation safety testing. This guide converts product-specific concentration, solubility, and dosing information into practical assay designs with controls, optimization checkpoints, and troubleshooting strategies.
-
Standardized Whole-Blood Stimulation for Immunometabolism
2026-08-17
Zhao and colleagues present a standardized whole-blood stimulation protocol that combines immune challenges with targeted metabolic interventions to measure cytokine responses in a physiologically complex system. The approach improves comparability across cohort studies and helps define how glycolysis, fatty-acid oxidation, and other metabolic pathways selectively shape immune activation.
-
Thioredoxin Control of CHK1 Inhibitor Sensitivity
2026-08-17
The reference study identifies thioredoxin 1 as a determinant of checkpoint kinase 1 inhibitor sensitivity in non-small cell lung cancer and links this response to redox recycling of ribonucleotide reductase subunit RRM1. Its findings support a mechanistically focused combination strategy in which thioredoxin reductase inhibition disrupts deoxynucleotide production and reinforces replication-stress–based cancer therapy.
-
SB 431542: Practical ALK5 Inhibitor Workflows
2026-08-16
SB 431542 provides selective control of ALK5-linked TGF-β signaling for mechanistic studies spanning stem-cell organoids, glioma models, and immune assays. This guide translates its Smad2-focused mechanism into practical dosing, validation, troubleshooting, and experimental-design strategies.
-
Tetracycline C6589 for Reliable Cell Assays
2026-08-15
A scenario-driven guide to using Tetracycline (SKU C6589) in microbiological selection and cell-based viability or proliferation workflows. It explains mechanism, assay controls, stock preparation, data interpretation, and practical criteria for choosing a quality-controlled reagent.
-
NP-40 Lysis Buffer for Neuroimmune Assays
2026-08-14
NP-40 Lysis Buffer provides a mild, non-denaturing route to protein extracts for Western blotting, immunoprecipitation, co-immunoprecipitation, PAGE, and ELISA. This workflow translates FPR2/ALX neuroinflammation findings into practical sample-preparation choices while preserving phosphoproteins and native protein associations.
-
Axitinib (AG 013736): From Mechanism to Translation
2026-08-14
A translational framework for using Axitinib (AG 013736) to connect VEGFR-selective mechanism, angiogenesis inhibition assays, response measurement, xenograft interpretation, and reproducible cancer biology research.
-
CDK9 inhibitor (A3294): Practical Lab Guide
2026-08-13
CDK9 inhibitor (A3294) is a selective serine/threonine kinase inhibitor for studying CDK9-dependent transcription elongation and P-TEFb-related processes. It is appropriate for focused biochemical, cell viability, and MT4 HIV-1 research workflows, but not for broad-spectrum CDK inhibition or long-term storage of prepared solutions.
-
Triterpene Prodrug for Targeted Oral Cancer Therapy
2026-08-13
The reference study develops a carrier-free, self-assembled prodrug that combines glycyrrhetinic acid and ginsenoside Rh2 for reactive oxygen species-responsive treatment of oral squamous cell carcinoma. Its central innovation is a self-reinforcing mechanism in which tumor-associated ROS releases the active triterpenes while glycyrrhetinic acid generates additional ROS, strengthening oxidative stress and apoptosis.
-
PD98059 MEK Inhibitor: Workflows and Applications
2026-08-12
PD98059 provides reversible pharmacological control of MEK-to-ERK signaling for studies of cell-cycle arrest, apoptosis, oxidative injury, and neuroprotection. This practical guide connects pathway validation with reproducible dosing, readout selection, and troubleshooting across leukemia, liver-injury, and ischemia-related models.